Tobias,
I've normally found the IR guy (Paul Hughes quite accommodating). The trial failed its primary endpoint as other posters have pointed out, by it including significance 'though'' 24 months - it was just over 0.05 at 6 months, but well under at 12 and 24. I am no trial expert and understand the FDA may have been insistent, but it would have been nice for them to explain (or an analyst to ask) why they had a six month review (the only where significance was not met) in a pathogenisis that evolves over years and is never going to show significant improvements at the six month mark
I will not be popular for saying it, and perhaps the FDA was the culprit with trial discussions, but having a six month end point in a chronic degenerative disc disease trial seems absurdly optimistic and onerous to a regulatory trial in my opinion. Whilst MSB has certainly been the brunt of some unfortunate circumstances and decisions in its trials, I am getting very tired of the clear suggestions of efficacy, but failure of endpoints for regulatory purposes. At $2.60 MSB is a clear buy and why I am still in, but I for one understand your disappointment with some of the communication. I made the point in the past to Paul (that he did not disagree) that any trial failures should be readily and clearly explained to investors - CHF did include all of the MACE endpoints as pre-specified but it was not immediately obvious. I'd give MSB a C+ on this one at best....another buying opportunity for the long run. The treatments work, but patients and investors will alas have to wait longer for commercial availability.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-366
-
- There are more pages in this discussion • 738 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |